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Scleroderma Renal Crisis: Identifying Risk Factors
and Preventing Adverse Outcomes
Yesha K. Shah, DO, Joseph V. Moran, DO and Timothy B. Coyle, DO
Department of Medicine, Lehigh Valley Health Network, Allentown, Pennsylvania

Introduction

Scleroderma renal crisis (SRC) is
characterized by an abrupt onset of
severe hypertension that is typically
associated with increased plasma
renin activity and acute renal failure.
• Risk factors include a previous diagnosis of diffuse

scleroderma, positivity in RNA polymerase III IgG
autoantibodies and recent use of high dose glucocorticoids.
• This case presents a patient who was diagnosed with
scleroderma renal crisis after a two week course of steroids.
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Case Presentation

Discussion

small cell lung cancer (NSCLC) with metastasis to the brain
and diffuse scleroderma presented to the emergency
department with a three day history of fatigue and weakness.
• She had been receiving radiation therapy for her brain
metastases and was concurrently taking dexamethasone
4 mg daily.
• One month prior to admission, the patient was seen by
rheumatology for scleroderma follow up at which point
positivity of RNA polymerase III autoantibodies was seen on
lab work.
• On admission she had profoundly elevated blood pressures
without a longstanding history of hypertension. Lab work
revealed a hemolytic anemia and acute renal failure
complicated by hyperkalemia and a creatinine 7x her
baseline. Urinalysis showed proteinuria and hematuria.
• Suspicion for SRC was high, but due to hyperkalemia, ACEInhibitors were held at admission. Emergent hemodialysis
was initiated and captopril was subsequently administered.
• Unfortunately, the patient’s hospital course was complicated
by septic shock and respiratory failure secondary to
pneumonia. Given her underlying NSCLC and poor prognosis
her family ultimately decided to proceed with comfort
measures only.

crisis, including a diagnosis of diffuse sclerosis, the presence
of autoantibodies directed against RNA polymerase III, and
recent steroid use.
• Given her risk factors, closer monitoring of her renal function
after starting the steroid regimen may have led to an earlier
diagnosis.
• Literature suggests that prompt diagnosis and treatment is
critical as this can slow irreversible renal injury. For high risk
patients, literature states that daily home blood pressure
measurements are recommended.
• Early recognition in this case was especially important
given her co-morbidities. By the time she was admitted,
her development of hyperkalemia and sepsis made
administration of ACE-Inhibitors more challenging.
• ACE Inhibitors are the initial treatment of choice for SRC,
with a goal of returning the patient back to his or her
baseline blood pressure within 72 hours.
• If there is central nervous system involvement, intravenous
nitroprusside can be added for a short duration of therapy.
• Had this patient been diagnosed earlier, literature suggests
that ACE-Inhibitor therapy affects the survival rate at one
year significantly, from 15% to 76%.

• A 57-year-old female with a past medical history of non-

• This patient had multiple risk factors for scleroderma renal
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